Cell Source

Cell Source Net Income

The Net Income of Cell Source (CLCS) as of Nov 15, 2026 is -4.64 M USD. In the previous year, Net Income was -4.77 M USD — a change of -2.79% (higher).

Net Income

-4.64 MUSD

YoY

-2.79%

Last updated:

In 2025, Cell Source's profit amounted to -4.64 M USD, a -2.79% increase from the -4.77 M USD profit recorded in the previous year.

The Cell Source Net Income history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Income
Date
Net Income
Jan 1, 2018
-2.12 M USD
Jan 1, 2019
-4.48 M USD
Jan 1, 2020
-5.50 M USD
Jan 1, 2021
-5.47 M USD
Jan 1, 2022
-5.17 M USD
Jan 1, 2023
-5.17 M USD
Jan 1, 2024
-4.77 M USD
Jan 1, 2025
-4.64 M USD
The Cell Source Net Income history
YEARNet IncomeYoY
-4.64 MUSD-2.79%
-4.77 MUSD-7.68%
-5.17 MUSD0.00%
-5.17 MUSD-5.56%
-5.47 MUSD-0.47%
-5.50 MUSD+22.85%
-4.48 MUSD+111.38%
-2.12 MUSD-31.32%
-3.08 MUSD+218.44%
-968,000.00USD-61.34%
-2.50 MUSD-38.28%
-4.06 MUSD+15,730.96%
-25,627.00USD+1,442.02%
-1,661.91USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cell Source Revenue

Cell Source Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2018
0.00 USD
-2.01 M USD
-2.12 M USD
Jan 1, 2019
0.00 USD
-3.81 M USD
-4.48 M USD
Jan 1, 2020
0.00 USD
-3.64 M USD
-5.50 M USD
Jan 1, 2021
0.00 USD
-4.02 M USD
-5.47 M USD
Jan 1, 2022
0.00 USD
-4.18 M USD
-5.17 M USD
Jan 1, 2023
0.00 USD
-4.18 M USD
-5.17 M USD
Jan 1, 2024
0.00 USD
-3.85 M USD
-4.77 M USD
Jan 1, 2025
0.00 USD
-2.73 M USD
-4.64 M USD

Cell Source Margins

Cell Source stock margins

The Cell Source margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Cell Source. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Cell Source.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2018
0.00 %
- %
- %
Jan 1, 2019
0.00 %
- %
- %
Jan 1, 2020
0.00 %
- %
- %
Jan 1, 2021
0.00 %
- %
- %
Jan 1, 2022
0.00 %
- %
- %
Jan 1, 2023
0.00 %
- %
- %
Jan 1, 2024
0.00 %
- %
- %
Jan 1, 2025
0.00 %
- %
- %

Cell Source Stock analysis

What does Cell Source do? Cell Source, Inc. generates revenue through the development and commercialization of its Veto Cell immune system management technology, which selectively blocks immune responses in allogeneic hematopoietic stem cell transplantation (HSCT). The company's lead product, Veto Cell technology, is in pre-clinical phase and targets haploidentical stem cell transplants under mild conditioning regimens. Its product pipeline includes VETO CAR-T therapies for B-cell malignancies and solid tumors, as well as Veto Cell applications for kidney and liver transplants and Veto HSCT for non-malignant disorders. The firm's wholly owned subsidiary, Cell Source Limited (CSL), supports these initiatives. Cell Source, Inc. focuses on developing immune tolerance biotechnology for clinical applications, targeting healthcare providers and transplant centers that require solutions for immune response management. The company's Veto Cell technology aims to enable safer and more effective allogeneic HSCT procedures, particularly for patients needing haploidentical transplants. The firm's pipeline products, including VETO CAR-T and Veto Cell kidney and liver transplants, are designed to address unmet needs in oncology and organ transplantation markets. The company's revenue model relies on the future commercialization of its proprietary technologies, with Veto Cell technology as the cornerstone. Its pre-clinical stage products, such as VETO CAR-T for B-cell malignancies and Veto Cell liver transplants, are positioned to enter clinical trials and eventually reach the market. Cell Source Limited (CSL) operates as a wholly owned subsidiary to advance these therapeutic approaches within the cell therapy sector. Cell Source is one of the most popular companies on Eulerpool.

Net Income Details

Understanding Cell Source's Profit Margins

The profit margins of Cell Source represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Cell Source's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Cell Source's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Cell Source's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Cell Source’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Cell Source stock

Net Income of Cell Source is -4.64 M USD in 2025.

Net Income of Cell Source changed from -4.77 M USD to -4.64 M USD, representing a -2.79% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Income Cell Source since 2006 – with annual values, charts, and detailed analysis.

The achievement of a profit is the biggest goal of a company. The profit can be used for distribution or reinvestment. The profit (also called annual surplus or EAT, earnings after taxes) is the positive difference between income and expenses in a period as shown in the income statement. A negative annual surplus is called annual loss. Both performance measures are also combined under the neutral term annual result.

The Net Income is derived from all revenues / sales minus the expenses in the period under review. The following overview clearly shows which positions contribute to the annual surplus and where the differences lie compared to other variants of profit such as EBT, EBIT, and EBITDA.

Net Income's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Income's Cell Source historically and in real time.

The profit in evaluating a stock

History, usage, calculation, and application of earnings in securities trading.

The history of earnings dates back to the beginnings of modern business organization. Since the beginning of industrialization, companies have been established to generate profits, and profits have been considered an essential part of corporate management. In recent years, the importance of earnings for investors has continued to rise, as many investors seek to find stocks that generate solid earnings.

Use of Profits

In securities trading, profits are used to determine the value of a stock. A company that generates profits is considered financially healthy and its stocks are valued higher, while a company that does not generate profits is considered less reliable and therefore receives a lower valuation. Investors can review the profits of each company by examining the relevant documents such as the income statement, the annual financial statements, and the income tax audits.

Calculation of profits

There are several different ways to calculate profits. The simplest way to calculate profits is by calculating net earnings. Net earnings are calculated by subtracting the company's expenses from its revenue. Another way to calculate profits is by calculating operating income. Operating income is calculated by subtracting the company's materials costs and employee wages and salaries from its revenue.

Use of profits

There are many different ways in which investors can use profits when evaluating stocks. One example is calculating the price-to-earnings ratio (P/E ratio). The P/E ratio is the relationship between the price of a stock and the company's earnings. When calculating the P/E ratio, the stock price is divided by the company's earnings. A low P/E value indicates that the stock has a good price-performance ratio, and a high P/E value indicates that the stock has a poor price-performance ratio.

Advantages and disadvantages of using profits

There are many advantages to using earnings in securities trading. Firstly, investors can check the financial health of a company by analyzing earnings. Secondly, investors can make a better decision about the valuation of a stock by calculating the P/E ratio. Thirdly, investors can reduce their risk by choosing stocks with a low P/E ratio.

However, there are also some drawbacks to relying on profits. Firstly, profits can be distorted if a company increases its profits through cost-cutting measures. Secondly, profits can present an inaccurate picture of a company's financial health if they are not calculated correctly. Thirdly, profits may not always be a reliable indicator of a company's future, as they can easily fluctuate.

t('components_kpi_Explanation_34')

Overall, it can be said that profits in securities trading are an important indicator of a company's financial health. Investors can analyze profits to get a better understanding of the company's financial health and make informed decisions about stock valuation. However, there are some disadvantages to using profits as they can sometimes be distorted or inaccurate. Therefore, it is important for investors to be cautious and carefully analyze profits before making a decision to buy or sell stocks.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Cell Source

All Key Metrics — Cell Source